The global non-surgical bio-implants market has set a valuation of US$ 27.8 Bn in 2021, and further, is expected to expand at a CAGR of 13.2% to reach US$ 96.0 Bn by the year 2032.
“Increasing adoption of bio-implant procedures and advancements in the bioengineering technologies is expected to uplift the non-surgical bio-implants market growth.”
An implant is a manufactured medical device that is inserted into a human body cavity to replace, support, or augment a biological structure that is missing, damaged, or already present. The prosthesis known as "bio-implants" are used to normalize a person's physiological functions.
The physiology that has been damaged, deregulated, or lost can be effectively restored, replaced, or modulated with injectable bio-implants, a non-surgical therapy approach. The number of people over the age of 60 and above resulted to continue the global trend of rising life expectancy and declining mortality rates.
Globally, the geriatric population is expanding faster than any other age group, demanding an effective and safe treatment for age-related conditions. This has grabbed the attention of non–surgical bio-implants.
| Attributes | Details |
|---|---|
| Non-Surgical Bio-Implants Market Value in 2021 | US$ 27.8 Billion |
| Non-Surgical Bio-Implants Market Value in 2032 | US$ 96.0 Billion |
| Non-Surgical Bio-Implants Market CAGR (2022 to 2032) | 13.2% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The major drivers for the growth of the non-surgical implants market are growing concern for chronic disorders, a high level of healthcare awareness, and a growing geriatric population. In addition, the growing disposable incomes of people and the rising application areas majorly medical and aesthetic for biomaterials used in non-surgical bio-implants will attribute the market growth.
Furthermore, the advancements in technology in bio-implants and the affordable cost with easy availability of bio-implants are expected to have strong growth in the market. Apart from this, the demand for bio-implants in several medical applications is fuelling market growth.
Owing to a large number of key players and strong healthcare infrastructure, North America is expected to share the highest market for non-surgical bio-implants in the projected years.
Europe is the largest market for non-surgical bio-implants after North America due to the technological advancements in the region, along with increasing government support and funding and rising research and development activities.
Furthermore, due to the increasing geriatric population in the developing countries and high disposable income, the Asia Pacific region is expected to develop a lucrative market for non-surgical bio-implants market in near future.
Principal Consultant
Some of the market players operating in the non-surgical bio-implants market are Albiorex International, Moma Therapeutics, Inc., FibroGen, Inc., KYTHERA Biopharmaceuticals, Inc., Novatex Bioengineering SA, Anika Therapeutics, Inc., Johnson & Johnson Private Limited, Fidia Farmaceutici S.p.A., LCA Pharmaceuticals, Hangzhou Gallop Biological Products Co., Ltd., and others.
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 13.2% 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Billion, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segment Covered | Type, Region |
| Region Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, Malaysia, Singapore, Australia, New Zealand, GCC, South Africa, Israel |
| Key Players | Albiorex International; Moma Therapeutics, Inc.; FibroGen, Inc.; KYTHERA Biopharmaceuticals, Inc.; Novatex Bioengineering SA; Anika Therapeutics, Inc.; Johnson & Johnson Private Limited; Fidia Farmaceutici S.p.A.; LCA Pharmaceuticals; Hangzhou Gallop Biological Products Co., Ltd. |
| Customization | Available Upon Request |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global non-surgical bio-implants market is anticipated to register a CAGR of 13.2% during the forecast period.
The top players in the global non-surgical bio-implants market are Albiorex International Moma Therapeutics, Inc., FibroGen, Inc., KYTHERA Biopharmaceuticals, Inc., Novatex Bioengineering SA, and others.
Explore Healthcare Insights
View Reports
Non-Surgical Bio-Implants Market
